MXPA04005123A - Agonistas del receptor activado por proliferador de peroxisoma. - Google Patents

Agonistas del receptor activado por proliferador de peroxisoma.

Info

Publication number
MXPA04005123A
MXPA04005123A MXPA04005123A MXPA04005123A MXPA04005123A MX PA04005123 A MXPA04005123 A MX PA04005123A MX PA04005123 A MXPA04005123 A MX PA04005123A MX PA04005123 A MXPA04005123 A MX PA04005123A MX PA04005123 A MXPA04005123 A MX PA04005123A
Authority
MX
Mexico
Prior art keywords
methyl
acid
oxo
benzyl
phenoxy
Prior art date
Application number
MXPA04005123A
Other languages
English (en)
Spanish (es)
Inventor
Larry Winneroski Junio Leonard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA04005123A publication Critical patent/MXPA04005123A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MXPA04005123A 2001-11-30 2002-11-26 Agonistas del receptor activado por proliferador de peroxisoma. MXPA04005123A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33445301P 2001-11-30 2001-11-30
PCT/US2002/036128 WO2003048130A2 (en) 2001-11-30 2002-11-26 Peroxisome proliferator activated receptor agonists

Publications (1)

Publication Number Publication Date
MXPA04005123A true MXPA04005123A (es) 2005-02-17

Family

ID=23307275

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005123A MXPA04005123A (es) 2001-11-30 2002-11-26 Agonistas del receptor activado por proliferador de peroxisoma.

Country Status (19)

Country Link
US (1) US7544812B2 (enExample)
EP (1) EP1453811A2 (enExample)
JP (1) JP2005517643A (enExample)
KR (1) KR20050044606A (enExample)
CN (1) CN1582279A (enExample)
AU (1) AU2002356927A1 (enExample)
BR (1) BR0214437A (enExample)
CA (1) CA2468846A1 (enExample)
CO (1) CO5640129A2 (enExample)
EA (1) EA007163B1 (enExample)
HR (1) HRP20040469A2 (enExample)
HU (1) HUP0402486A3 (enExample)
IL (1) IL161578A0 (enExample)
MX (1) MXPA04005123A (enExample)
NO (1) NO20042737L (enExample)
NZ (1) NZ532909A (enExample)
PL (1) PL370515A1 (enExample)
WO (1) WO2003048130A2 (enExample)
ZA (1) ZA200404173B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311834A (pt) 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE10351859A1 (de) * 2003-11-06 2005-06-09 Beiersdorf Ag Emulsionen mit zwei Verdickungsmitteln
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
NZ553566A (en) * 2004-09-28 2010-11-26 Allergan Inc Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
BRPI0713320A2 (pt) 2006-06-20 2012-02-07 Wyeth Corp inibidores de canal de potássio imidazola kvl.5
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CN101875636B (zh) * 2010-05-18 2012-01-04 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452041A (en) * 1965-05-19 1969-06-24 American Home Prod Hydantoin compounds and methods of preparation
CA1176261A (en) 1976-06-03 1984-10-16 Albert G. Caldwell Hydantoin derivatives
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS59159163A (ja) * 1983-03-01 1984-09-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−感光材料
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1998039303A1 (en) * 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Also Published As

Publication number Publication date
NO20042737L (no) 2004-08-17
PL370515A1 (en) 2005-05-30
US7544812B2 (en) 2009-06-09
WO2003048130A2 (en) 2003-06-12
HUP0402486A3 (en) 2007-05-02
CO5640129A2 (es) 2006-05-31
HRP20040469A2 (en) 2004-10-31
CN1582279A (zh) 2005-02-16
AU2002356927A1 (en) 2003-06-17
KR20050044606A (ko) 2005-05-12
CA2468846A1 (en) 2003-06-12
EA200400748A1 (ru) 2004-12-30
JP2005517643A (ja) 2005-06-16
BR0214437A (pt) 2004-10-13
EA007163B1 (ru) 2006-08-25
WO2003048130A3 (en) 2003-11-20
US20050020652A1 (en) 2005-01-27
HUP0402486A2 (hu) 2005-03-29
EP1453811A2 (en) 2004-09-08
IL161578A0 (en) 2004-09-27
ZA200404173B (en) 2005-08-23
NZ532909A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
MXPA04005123A (es) Agonistas del receptor activado por proliferador de peroxisoma.
KR100839705B1 (ko) 트리아졸 유도체 및 그의 퍼옥시좀 증식제 활성화 수용체 알파 효능제로서의 용도
DE60129712T2 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
AU2002228592A1 (en) Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
DE60128239T2 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
WO2008117982A1 (en) Heterocyclic carboxylic acid derivatives and pharmaceutical composition for inhibiting lipid accumulation containing same
DE60131001T2 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
US7220880B2 (en) Amide linker peroxisome proliferator activated receptor modulators
NZ542242A (en) Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
HK1058790B (en) Peroxisome proliferator activated receptor alpha agonists